1
|
Zmysłowska A, Jakiel P, Gadzalska K, Majos A, Płoszaj T, Ben-Skowronek I, Deja G, Glowinska-Olszewska B, Jarosz-Chobot P, Klonowska B, Kowalska I, Mlynarski W, Mysliwiec M, Nazim J, Noczynska A, Robak-Kontna K, Skala-Zamorowska E, Skowronska B, Szadkowska A, Szypowska A, Walczak M, Borowiec M. Next- generation sequencing is an effective method for diagnosing patients with different forms of monogenic diabetes. Diabetes Res Clin Pract 2022; 183:109154. [PMID: 34826540 DOI: 10.1016/j.diabres.2021.109154] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 11/13/2021] [Accepted: 11/20/2021] [Indexed: 11/03/2022]
Abstract
AIM Monogenic diabetes (MD) represents 5-7% of antibody-negative diabetes cases and is a heterogeneous group of disorders. METHODS We used targeted next-generation sequencing (NGS) on Illumina NextSeq 550 platform involving the SureSelect assay to perform genetic and clinical characteristics of a study group of 684 individuals, including 542 patients referred from 12 Polish Diabetes Centers with suspected MD diagnosed between December 2016 and December 2019 and their 142 family members (FM). RESULTS In 198 probands (36.5%) and 66 FM (46.5%) heterozygous causative variants were confirmed in 11 different MD-related genes, including 31 novel mutations, with the highest number in the GCK gene (206/264), 22/264 in the HNF1A gene and 8/264 in the KCNJ11 gene. Of the 183 probands with MODY1-5 diabetes, 48.6% of them were diagnosed at the pre-diabetes stage and most of them (68.7%) were on diet only at the time of genetic diagnosis, while 31.3% were additionally treated with oral hypoglycaemic drugs and/or insulin. CONCLUSIONS In summary, the results obtained confirm the efficacy of targeted NGS method in the molecular diagnosis of patients with suspected MD and broaden the spectrum of new causal variants, while updating our knowledge of the clinical features of patients defined as having MD.
Collapse
Affiliation(s)
- A Zmysłowska
- Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland.
| | - P Jakiel
- Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland
| | - K Gadzalska
- Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland
| | - A Majos
- Department of General and Transplant Surgery, Medical University of Lodz, Lodz, Poland
| | - T Płoszaj
- Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland
| | - I Ben-Skowronek
- Department of Pediatric Endocrinology and Diabetology, Medical University of Lublin, Lublin, Poland
| | - G Deja
- Department of Children's Diabetology, Medical University of Silesia in Katowice, Poland
| | - B Glowinska-Olszewska
- Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Bialystok, Bialystok, Poland
| | - P Jarosz-Chobot
- Department of Children's Diabetology, Medical University of Silesia in Katowice, Poland
| | - B Klonowska
- Department of Clinical Pediatrics, University of Warmia and Mazury in Olsztyn, Provincial Specialist Children's Hospital, Olsztyn, Poland
| | - I Kowalska
- Department of Internal Medicine and Metabolic Diseases, Medical University of Bialystok, Bialystok, Poland
| | - W Mlynarski
- Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland
| | - M Mysliwiec
- Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - J Nazim
- Department of Pediatric Endocrinology, Jagiellonian University Medical College, Cracow, Poland
| | - A Noczynska
- Department of Pediatric Endocrinology and Diabetology, Wroclaw Medical University, Wroclaw, Poland
| | - K Robak-Kontna
- Outpatient Clinic for Pediatric Diabetology, Regional Children's Hospital in Bydgoszcz, Bydgoszcz, Poland
| | - E Skala-Zamorowska
- Department of Children's Diabetology, Medical University of Silesia in Katowice, Poland
| | - B Skowronska
- Department of Pediatric Diabetes and Obesity, Poznan University of Medical Sciences, Poznan, Poland
| | - A Szadkowska
- Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, Lodz, Poland
| | - A Szypowska
- Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland
| | - M Walczak
- Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of the Developmental Age, Pomeranian Medical University in Szczecin, Szczecin, Poland
| | - M Borowiec
- Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland
| |
Collapse
|
2
|
Topor-Madry R, Wojtyniak B, Strojek K, Rutkowski D, Bogusławski S, Ignaszewska-Wyrzykowska A, Jarosz-Chobot P, Czech M, Kozierkiewicz A, Chlebus K, Jędrzejczyk T, Mysliwiec M, Polanska J, Wysocki MJ, Zdrojewski T. Prevalence of diabetes in Poland: a combined analysis of national databases. Diabet Med 2019; 36:1209-1216. [PMID: 30889281 DOI: 10.1111/dme.13949] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/15/2019] [Indexed: 12/15/2022]
Abstract
AIMS To assess the number of people with diabetes in Poland using combined national sources and to evaluate the usefulness of data from an insurance system for epidemiological purposes. METHODS The data were collected from four sources: 1) 2013 all-billing records of the national insurance system comprising people of all age groups undergoing procedures or receiving services in primary healthcare, specialist practices and hospitals and also those receiving drugs; 2) an epidemiological study, NATPOL, that involved the assessment of people with undiagnosed diabetes; 3) the RECEPTOmetr Sequence study on prescriptions; and 4) regional child diabetes registries. RESULTS In 2013, 1.76 million people (0.98 million women and 0.79 million men) had medical consultations (coded E10-E14) and 2.13 million people (1.19 million women and 0.94 million men) purchased drugs or strip tests for diabetes. A total of 0.04 million people who used medical services did not buy drugs. In total, the number of people with diabetes in the insurance system was 2.16 million (1.21 million women and 0.95 million men), which corresponds to 6.1% (95% CI 6.11-6.14) of women and 5.1% (95% CI 5.12-5.14) of men. Including undiagnosed cases, the total number of people with diabetes in Poland was 2.68 million in 2013. CONCLUSION The estimated prevalence of diabetes (diagnosed and undiagnosed cases) in Poland is 6.97%. Data from the national insurance system with full coverage of the population can be treated as a reliable source of information on diseases with well-defined diagnosis and treatment methods, combined with an assessment of the number of undiagnosed individuals.
Collapse
Affiliation(s)
- R Topor-Madry
- Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow
| | - B Wojtyniak
- National Institute of Public Health - National Institute of Hygiene, Warsaw
| | - K Strojek
- Department of Internal Diseases, Diabetology and Cardiometabolic Diseases, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice
| | | | | | | | - P Jarosz-Chobot
- Department of Children's Diabetology, Medical University of Silesia, Katowice
| | - M Czech
- Medical University in Warsaw, Warsaw
| | | | - K Chlebus
- Department of Cardiology, Clinical Center of Cardiology, Medical University of Gdansk, Gdansk
| | - T Jędrzejczyk
- Department of Preventive Medicine and Medical Education, Medical University of Gdansk, Gdansk
| | - M Mysliwiec
- Chair of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Gdansk
| | - J Polanska
- Data Mining Group, Silesian University of Technology, Gliwice, Poland
| | - M J Wysocki
- National Institute of Public Health - National Institute of Hygiene, Warsaw
| | - T Zdrojewski
- Department of Preventive Medicine and Medical Education, Medical University of Gdansk, Gdansk
| |
Collapse
|
3
|
D’Angelo V, Villa S, Mysliwiec M, Donati MB, de Gaetano G. Defective Fibrinolytic and Prostacyclin-Like Activity in Human Atheromatous Plaques. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646719] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- V D’Angelo
- Department of Neurosurgery, Ca.-Granda Hospital, Milan, Italy
| | - S Villa
- Department of Neurosurgery, Ca.-Granda Hospital, Milan, Italy
| | - M Mysliwiec
- On leave of absence from the Haematology Clinic, Institute of Internal Diseases, Medical School, Bialystok, Poland
| | - M B Donati
- Department of Neurosurgery, Ca.-Granda Hospital, Milan, Italy
| | - G de Gaetano
- Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via Eritrea, 62, 20157-Milan, Italy
| |
Collapse
|
4
|
Malyszko JS, Malyszko J, Azzadin A, Buczko W, Mysliwiec M. Conjugated Estrogens Shorten Bleeding Time in Uraemia: a Possible Role of Serotonin? Thromb Haemost 2018. [DOI: 10.1055/s-0038-1653744] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
| | | | - Arsalan Azzadin
- Pharmacodynamics Department, Medical School, Bialystok, Poland
| | - W Buczko
- Pharmacodynamics Department, Medical School, Bialystok, Poland
| | - M Mysliwiec
- Nephrology Department, Medical School, Bialystok, Poland
| |
Collapse
|
5
|
Chobot A, Polanska J, Brandt A, Deja G, Glowinska-Olszewska B, Pilecki O, Szadkowska A, Mysliwiec M, Jarosz-Chobot P. Updated 24-year trend of Type 1 diabetes incidence in children in Poland reveals a sinusoidal pattern and sustained increase. Diabet Med 2017; 34:1252-1258. [PMID: 28257151 DOI: 10.1111/dme.13345] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/27/2017] [Indexed: 12/11/2022]
Abstract
AIMS To present the incidence trend for Type 1 diabetes in Polish children aged 0-14 years, updated using data collected during 2005-2012, and assess the reliability of the predictive model constructed previously using the 1989-2004 database. METHODS Children aged < 15 years with newly diagnosed Type 1 diabetes are recorded prospectively (EURODIAB criteria) in several regional registers in Poland. Age- and gender-standardized incidence rates for Type 1 diabetes were calculated per 100 000 persons/year. Incidence rates were analysed in terms of the dependency on age, gender, geographical region and population density. Incidence rate trends over time were modelled using generalized linear models. RESULTS The mean standardized incidence for 1989-2012 was 12.72 per 100 000 persons/year [95% confidence interval (CI), 11.35 to 14.21]. Over the 24-year observation period, the incidence increased from 5.36 to 22.74 per 100 000 persons/year. The lowest incidence rate was in children aged 0-4 years (8.35, 95% CI 7.27 to 9.57 per 100 000 persons/year). There was no difference between genders, or urban and rural regions. Incidence rates were higher in northern compared with southern Poland [14.04 (95% CI 12.59 to 15.63) vs. 11.94 (95% CI 10.62 to 13.39) per 100 000 persons/year]. The new data corrected the earlier predictive model by changing the estimates of some factors related to patient age, gender and their interactions with the remaining factors. The incidence rate shows periodic 5.33-year fluctuations. The periodicity component allows for a more accurate prediction of the incidence rate over time. CONCLUSIONS This cohort study reveals a sustained increase in Type 1 diabetes incidence in Polish children aged 0-14 years with regular, sinusoidal fluctuations and a slight levelling off in past few years. It is of concern that are the highest increases in incidence are found in children aged 0-4 years.
Collapse
Affiliation(s)
| | - J Polanska
- Silesian University of Technology, Gliwice
| | - A Brandt
- Medical University of Gdansk, Gdansk
| | - G Deja
- Medical University of Silesia, Katowice
| | | | - O Pilecki
- Provincial Children's Hospital, Bydgoszcz
| | | | | | | |
Collapse
|
6
|
Imko-Walczuk B, Kielbowicz M, Malyszko J, Malyszko J, Barczyk M, Debska-Slizien A, Mysliwiec M, Rutkowski B. Kaposi Sarcoma in the Genital Area in a Kidney Transplant Patient: A Case Report and Literature Review. Transplant Proc 2017; 48:1843-8. [PMID: 27496505 DOI: 10.1016/j.transproceed.2016.01.070] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Accepted: 01/21/2016] [Indexed: 12/28/2022]
Abstract
BACKGROUND Kaposi sarcoma (KS) is a cancer with an incidence in patients after transplantation (Tx) that is 500 times greater than that in the healthy population. The risk of KS increases significantly during therapy, especially when immunosuppressive therapy with cyclosporine A (CsA) is used. Most cases of KS develop during the first 2 years after transplantation. After a KS diagnosis, it is recommended to reduce the doses of immunosuppressive medications. Conversion of immunosuppressive treatment into mammalian target of rapamycin (m-TOR) inhibitors is strongly suggested. PATIENTS AND METHODS We present the case of a 65-year-old man with end-stage renal disease (ESRD) of unknown etiology, who had kidney transplantation in 2008. Immunosuppressive protocol was based on CsA, mycophenolate mofetil (MMF) and prednisolone (PRE). In 2011, during the dermatological consultation, on the penis glans a purple stain of uneven surface was noted. Histology study revealed the presence of KS. The treatment was modified. The patient was converted from CsA to everolimus. Before converting, the creatinine concentration was 1.79 mg/dl and proteinuria less than 0.3 g/day. RESULTS The change in the scheme of immunosuppresion from CsA to everolimus was performed to treat the Kaposi sarcoma. Gradually, within a year, the KS was cured. However, the graft function deteriorated, and the graft was lost in one-years' time. CONCLUSION We present the first documented case of KS in the genital area of a kidney patient. The reduction in the strength of immunosuppression, and the introduction of an m-TOR inhibitor, may have contributed to the deterioration of kidney function, however it was substantial in the treatment of KS.
Collapse
Affiliation(s)
- B Imko-Walczuk
- Copernicus-Independent Public Healthcare Centre, Dermatology & Venereology Clinic, Gdansk, Poland; College of Health, Beauty and Education in Poznan, Poland.
| | - M Kielbowicz
- College of Health, Beauty and Education in Poznan, Poland
| | - J Malyszko
- 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bialystok, Poland
| | - J Malyszko
- 2nd Department of Nephrology Medical University, Bialystok, Poland
| | - M Barczyk
- 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bialystok, Poland
| | - A Debska-Slizien
- Chair & Clinic of Nephrology, Transplantology and Internal Medicine, Gdansk University of Medical Sciences, Gdansk, Poland
| | - M Mysliwiec
- 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bialystok, Poland
| | - B Rutkowski
- Chair & Clinic of Nephrology, Transplantology and Internal Medicine, Gdansk University of Medical Sciences, Gdansk, Poland
| |
Collapse
|
7
|
Chmara M, Zuk M, Mickiewicz A, Brandt A, Chlebus K, Kubalska J, Bautembach-Minkowska J, Stroniawska-Woźniak M, Bednarska-Makaruk M, Kłosiewicz-Latoszek L, Rynkiewicz A, Mysliwiec M, Gruchala M, Limon J, Wasag B. Molecular basis of familial hypercholesterolemia in Poland – update from the Polish national centre of diagnostics and treatment of familial hypercholesterolemia. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.354] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Kakareko K, Rydzewska-Rosolowska A, Brzosko S, Gozdzikiewicz-Lapinska J, Koc-Zorawska E, Samocik P, Kozlowski R, Mysliwiec M, Naumnik B, Hryszko T. Renal Handling of Sclerostin in Response to Acute Glomerular Filtration Decline. Horm Metab Res 2016; 48:457-61. [PMID: 27214309 DOI: 10.1055/s-0042-107791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Deterioration of glomerular filtration rate (GFR) is associated with alterations of bone metabolism. It translates clinically to bone fragility and increased fractures rate among patients with impaired GFR. Recently, sclerostin (SCL) gained much attention as an important factor in pathogenesis of mineral and bone disturbances in patients with renal diseases. There is no data about SCL behaviour in patients with acute GFR decline. The aim of this study was to evaluate the renal handling of SCL. This is a prospective, single-centre observational study in patients undergoing nephrectomy due to urological indications. Serum and urinary SCL levels were measured prior and after nephrectomy. 25 patients were enrolled. After surgery, eGFR significantly declined (from 87.4±19.7 to 67.7±25.7 ml/min/1.73 m(2), p<0.0001). Nephrectomy caused more than 20 times higher renal fractional excretion of SCL [0.15 (interquartile range, IQR 0.09-0.40) vs. 2.78 (IQR 1.51-4.02)%, p<0.001], while its serum level remained intact [0.69 (IQR 0.57-0.90 vs. 0.65 (IQR 0.53-0.88) ng/ml, p=0.4]. The magnitude of eGFR reduction was associated inversely with change in urinary SCL fractional excretion (r=-0.6, p=0.001) and with alteration in serum SCL level (r=-0.5, p=0.01). Our results suggest that increased serum SCL concentrations at moderately reduced GFR are not due to diminished renal clearance. At more severely decreased GFR, elevated SCL concentration results from both increased production and reduced renal elimination.
Collapse
Affiliation(s)
- K Kakareko
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| | - A Rydzewska-Rosolowska
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| | - S Brzosko
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| | - J Gozdzikiewicz-Lapinska
- II Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Poland
| | - E Koc-Zorawska
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| | - P Samocik
- Department of Oncological and General Urology, J. Sniadecki Provincial Hospital, Bialystok, Poland
| | - R Kozlowski
- Department of Oncological and General Urology, J. Sniadecki Provincial Hospital, Bialystok, Poland
| | - M Mysliwiec
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| | - B Naumnik
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| | - T Hryszko
- I Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Poland
| |
Collapse
|
9
|
Zmyslowska A, Fendler W, Szadkowska A, Borowiec M, Mysliwiec M, Baranowska-Jazwiecka A, Buraczewska M, Fulmanska-Anders M, Mianowska B, Pietrzak I, Rzeznik D, Mlynarski W. Glycemic variability in patients with Wolfram syndrome is lower than in type 1 diabetes. Acta Diabetol 2015; 52:1057-62. [PMID: 25916214 PMCID: PMC4628085 DOI: 10.1007/s00592-015-0757-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 04/12/2015] [Indexed: 01/02/2023]
Abstract
AIMS Wolfram syndrome (WFS) is diagnosed as coexistence of diabetes mellitus and optic atrophy, where pancreatic beta cell destruction is associated with neurodegeneration. Typically, WFS necessitates insulin treatment similar to type 1 diabetes (T1D), but the mechanism of beta cell mass reduction leading to hyperglycemia is different. METHODS The aim of the study was to assess glycemic variability using the continuous glucose monitoring (CGM) system in seven pediatric patients with genetically confirmed WFS and compare the results with data obtained from 21 propensity score-matched patients with T1D. The "GlyCulator" application was used for the calculation of glycemic variability indices. RESULTS CGM recordings showed similarities in glycemic variability among WFS patients, but differing from those of the T1D group. Coefficient of variation (%CV), CONGA4h, and GONGA6h were significantly (p < 0.05) lower in WFS patients (28.08 ± 7.37, 54.96 ± 11.92, and 55.99 ± 10.58) than in T1D patients (37.87 ± 14.24, 74.12 ± 28.74, p = 0.02, and 80.26 ± 35.05, respectively). In WFS patients, the percentage of values above 126 mg/dL was 69.79 (52.08-77.43), whereas in patients with T1D, the percentage was significantly lower-47.22 (35.07-62.85, p = 0.018). Curiously, a tendency toward a lower percentage of measurements below 70 mg/dL was noted in the WFS group [0 (0-7.29)] in comparison with the T1D group [6.25 (0-18.06), p = 0.122]. WFS patients had a significantly higher C-peptide level (0.31 ± 0.2 ng/mL) than T1D patients (0.04 ± 0.04 ng/mL; p = 0.006). CONCLUSIONS Patients with WFS show smaller glycemic variability than individuals with T1D, and this may be associated with persistent residual insulin secretion.
Collapse
Affiliation(s)
- A Zmyslowska
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland.
| | - W Fendler
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - A Szadkowska
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - M Borowiec
- Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland
| | - M Mysliwiec
- Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdańsk, Poland
| | - A Baranowska-Jazwiecka
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - M Buraczewska
- Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdańsk, Poland
| | - M Fulmanska-Anders
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - B Mianowska
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - I Pietrzak
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - D Rzeznik
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland
| | - W Mlynarski
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna Str. 36/50, 91-738, Lodz, Poland.
| |
Collapse
|
10
|
Kluk A, Sznitowska M, Brandt A, Sznurkowska K, Plata-Nazar K, Mysliwiec M, Kaminska B, Kotlowska H. Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot study. Int J Pharm 2015; 485:1-6. [DOI: 10.1016/j.ijpharm.2015.02.068] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 02/24/2015] [Accepted: 02/27/2015] [Indexed: 11/28/2022]
|
11
|
Pawlak D, Mysliwiec M, Pawlak K. Oxidized low-density lipoproteins (oxldl) plasma levels and oxldl to ldl ratio – are they real oxidative stress markers in dialysed patients? Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Pawlak K, Mysliwiec M, Pawlak D. Oxldl – the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Fendler W, Małachowska B, Baranowska-Jazwiecka A, Borowiec M, Wyka K, Malecki MT, Jarosz-Chobot P, Mysliwiec M, Mlynarski W. Population-based estimates for double diabetes amongst people with glucokinase monogenic diabetes, GCK-MODY. Diabet Med 2014; 31:881-3. [PMID: 24660669 DOI: 10.1111/dme.12449] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 12/23/2013] [Accepted: 12/27/2013] [Indexed: 11/30/2022]
Affiliation(s)
- W Fendler
- Department of Paediatrics, Oncology, Haematology and Diabetology
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Tracz A, Madzio J, Gnys P, Malachowska B, Borowiec M, Wyka K, Jarosz-Chobot P, Mysliwiec M, Szadkowska A, Mlynarski W, Fendler W. Genetic variability of GCKR alters lipid profiles in children with monogenic and autoimmune diabetes. Exp Clin Endocrinol Diabetes 2014; 122:503-9. [PMID: 24918535 DOI: 10.1055/s-0034-1375648] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PURPOSE Mutations in the glucokinase (GCK) gene are associated with altered blood glucose and lipid concentrations. Our aim was to assess the effects on HbA1c and serum lipid levels of single nucleotide polymorphisms (SNPs) in 2 genes encoding proteins that interact with glucokinase: glucose-6-phospatase catalytic subunit 2 (G6PC2) and glucokinase regulatory protein (GCKR). METHODS The study group included 129 children with GCK-MODY from the Polish Registry of Monogenic Diabetes and 395 with type 1 diabetes (T1DM), in whom we genotyped 2 SNPs in G6PC2 (rs560887) and GCKR (rs1260326). Lipid concentrations were assessed in fasting serum samples. RESULTS Total and HDL cholesterol concentrations were significantly lower in the GCK-MODY group than in patients with T1DM (167.5±32.5 mg/dl vs. 174.4±31.1 mg/dl, p=0.0435 and 48.42±14.3 mg/dl vs. 58.7±12.7 mg/dl, p<0.0001, respectively). No differences in genotype distributions were found except for underrepresentation of GCKR TT homozygotes among GCK-MODY patients (10.9% in GCK-MODY vs. 17.7% in T1DM, p=0.0651). GCKR genotypes showed significant associations with lipid profiles and HbA1c levels, whereas no such associations were noted for G6PC2. After adjustment for confounders, TT homozygotes were shown to have higher total cholesterol and marginally higher LDL cholesterol and triglyceride levels (p=0.0245, p=0.0657 and p=0.0550, respectively). The difference between TT homozygotes and other genotypes was similar in magnitude within the GCK-MODY and T1DM groups. No significant interactions between the type of diabetes and the GCKR or G6PC2 genotype were detected. CONCLUSIONS Individuals who are homozygous TT at rs1260326 of the GCKR gene have higher triglyceride, total and LDL cholesterol levels regardless of the presence of GCK mutations.
Collapse
Affiliation(s)
- A Tracz
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - J Madzio
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - P Gnys
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - B Malachowska
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - M Borowiec
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - K Wyka
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - P Jarosz-Chobot
- Department of Pediatrics, Endocrinology and Diabetes, Silesian Medical University of Katowice, Poland
| | - M Mysliwiec
- Department of Pediatrics, Oncology, Hematology and Endocrinology, Medical University of Gdansk, Poland
| | - A Szadkowska
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - W Mlynarski
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | - W Fendler
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Poland
| | | |
Collapse
|
15
|
Koc-Zorawska E, Przybylowski P, Malyszko JS, Mysliwiec M, Malyszko J. Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients. Transplant Proc 2014; 45:2009-12. [PMID: 23769096 DOI: 10.1016/j.transproceed.2013.01.103] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2012] [Revised: 01/15/2013] [Accepted: 01/31/2013] [Indexed: 02/07/2023]
Abstract
BACKGROUND VAP-1 (vascular adhesion protein-1) is a copper-containing SSAO (semicarbazide-sensitive amine oxidase) secreted by vascular smooth muscle cells, adipocytes, and endothelial cells. Elevation of SSAO activity is observed in atherosclerosis, diabetes mellitus, and obesity. The aim of the study was to assess VAP-1 in prevalent heart and kidney allograft recipients. METHODS Complete blood count, urea, serum lipids, fasting glucose, and creatinine were studied by standard laboratory methods. VAP-1, N-terminal pro brain natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) were estimated using commercially available assays. RESULTS Healthy volunteers showed higher hemoglobin and estimated glomerular filtration rate (eGFR) but lower creatinine, NT-proBNP, hsCRP and VAP-1 relative to heart and kidney transplantation (OHT) (KTx). Among heart transplant recipients, VAP-1 correlated with age, presence of diabetes, insulin therapy, ejection fraction, estimated glomerular filtration rate by MDRD (Modification of Diet in Renal Disease), eGFR by CKD-EPI (Chronic Kidney Disease-Epidemiological Collaboration), use of tacrolimus, LVIDd (left ventricular internal end-diastolic dimension), New York Heart Association class and NT-proBNP. VAP-1 was significantly lower among patients treated with tacrolimus than cyclosporine. Diabetic patients versus nondiabetic subjects as well as patients with eGFR below 60 versus ≥ 60 mL/min showed higher serum VAP-1 in OHT and KTx populations. Multiple regression analysis revealed VAP-1 to be predicted in 25% by LVIDd, and use of tacrolimus in OHT. In kidney transplant recipients, VAP-1 correlated only with time after transplantation and serum glucose. CONCLUDING: VAP-1 elevations in heart transplant recipients were predominantly dependent on left ventricular diameter and use of tacrolimus; however, the precise associations with the immunosuppressive regimen warrant further studies. VAP-1 elevations in kidney transplant recipients may relate to glucose control.
Collapse
Affiliation(s)
- E Koc-Zorawska
- Department of Nephrology and Transplantology, Medical University, Bialystok, Poland
| | | | | | | | | |
Collapse
|
16
|
Zbroch E, Malyszko J, Glowinska I, Maciorkowska D, Kobus G, Mysliwiec M. Blood pressure control according to the prevalence of diabetes in renal transplant recipients. Transplant Proc 2013; 45:200-4. [PMID: 23375300 DOI: 10.1016/j.transproceed.2012.05.089] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Revised: 03/31/2012] [Accepted: 05/30/2012] [Indexed: 12/16/2022]
Abstract
Hypertension is one of the most frequent complications of renal transplantation. About 70% to 90% of this population display either high blood pressure (BP) or require antihypertensive therapy. Diabetes mellitus is also a common finding among kidney transplant recipients. The aim of the study was to assess the BP control among kidney transplant recipients according to the prevalence of diabetes. This retrospective analysis included 172 renal transplant recipients of overall mean age 50 years and 51% males. Hypertension was present in 79% of patients. About one-third of the studied population showed abnormal blood pressures based on office measurements. The cohort was divided into two groups according to the presence of diabetes: group 1, diabetic patients (n = 14) versus group 2, nondiabetics (n = 158). Nondiabetic patients were significantly older than diabetic ones (61.5 versus 49 years; P < .05) and their time after renal transplantation was longer (98.83 versus 67.33 months, P < .05). There was no difference in regard to hypertension prevalence, mean BP value, percentage of abnormal (≥ 140/90 mm Hg) BP values or glomerular filtration rate. Diabetic patients were prescribed less steroid. The main hypotensive drug used in whole cohort and in no-diabetic patients was a beta-blocker (n = 64, 37%; n = 4, 28%), patients with diabetes used beta-blockers and angiotensin-converting enzyme inhibitors at the same frequency (n = 60, 37%). The main causative factor for hypertension appeared to be the calcineurin inhibitor. More aggressive antihypertensive treatment using combined drugs, including RAS blockers, might provide adequate BP control among renal transplant subjects with high cardiovascular risk.
Collapse
Affiliation(s)
- E Zbroch
- Department of Nephrology and Transplantology with Dialysis Center, Medical University, Bialystok, Poland
| | | | | | | | | | | |
Collapse
|
17
|
Clotet S, Soler MJ, Rebull M, Pascual J, Riera M, Kucher AG, Parastaeva MM, Beresneva ON, Ivanova GT, Zaraysky MI, Artemeva AV, Kaukov IG, Smirnov AV, Roszkowska-Chojecka M, Walkowska A, Gawrys O, Olszynski K, Kompanowska-Jezierska E, Walkowska A, Roszkowska-Chojecka M, Gawrys O, Baranowska I, Kompanowska-Jezierska EM, Roszkowska-Chojecka MM, Dobrowolski L, Badzynska B, Olszynski KH, Lipkowski AW, Sadowski J, Kobayashi Y, Hirawa N, Okuyama Y, Fujita M, Fujiwara A, Saka S, Yatsu K, Toya Y, Yasuda G, Umemura S, Oliveira-Sales EB, Maquigussa E, Semedo P, Pereira LG, Camara NOS, Bergamaschi CT, Campos RR, Boim MA, Potenza MA, Sirolli V, Addabbo F, Di Pietro N, Amoroso L, Pipino C, Pandolfi A, Montagnani M, Bonomini M, Quiroz YJ, Rivero M, Yaguas K, Moran L, Rodriguez-Iturbe B, Lee J, Heo NJ, Kim S, Joo KW, Han JS, Rapp W, Raab S, Sprecher U, Funk J, Apfel CM, Conde-Knape K, Qin Y, Mou L, Li X, Li X, Ilatovskaya ME, Andreev-Andrievsky AA, Pozdnev VF, Iliyn AV, Medvedeva NA, Malyszko J, Koc-Zorawska E, Zbroch E, Malyszko JS, Zorawski M, Mysliwiec M, Wakui H, Tamura K, Masuda SI, Tsurumi-Ikeya Y, Fujita M, Kanaoka T, Fujikawa T, Suzuki S, Kobayashi Y, Yabana M, Toya Y, Umemura S, Iimuro S, Imai E, Matsuo S, Watanabe T, Nitta K, Akizawa T, Makino H, Ohashi Y, Hishida A. Hypertension - experimental models. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Przybylowski P, Koc-Zorawska E, Malyszko J, Mysliwiec M, Malyszko J. Renalase and Endothelial Dysfunction in Heart Transplant Recipients. Transplant Proc 2013; 45:394-6. [DOI: 10.1016/j.transproceed.2012.02.042] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Accepted: 02/28/2012] [Indexed: 12/21/2022]
|
19
|
Przybylowski P, Koc-Zorawska E, Glowinska I, Levin-Iaina N, Macdougall I, Malyszko J, Mysliwiec M, Malyszko J. Hemojuvelin and Iron Metabolism in Kidney and Heart Allograft Recipients. Transplant Proc 2013; 45:391-3. [DOI: 10.1016/j.transproceed.2012.02.041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Accepted: 02/28/2012] [Indexed: 11/25/2022]
|
20
|
Malyszko J, Glowinska I, Mysliwiec M. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression? Transplant Proc 2012. [PMID: 23195016 DOI: 10.1016/j.transproceed.2012.06.070] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Anemia is more prevalent in allograft recipients compared with glomerular filtration rate (GFR) matched patients with chronic kidney diseases. There is a paucity of data concerning the correction of anemia in the posttransplant period with erythropoietin-stimulating agents (ESA). The aim of this study was to compare the iron status, kidney function, inflammatory state, use of drugs affecting erythropoiesis (immunosuppressants ACEi/ARB) and correction of anemia using ESA in a chronic kidney disease (CKD) population versus kidney transplant recipients. We included 67 patients treated with ESA including 17 after kidney transplantation. CKD Patients with native kidneys were significantly older than allograft recipients (mean age 69 versus 51 years; P < .001, and despite similar serum creatinine and iron parameters showed an estimated lower GFR (19 mL/min versus 23 mL/min; P < .05). Median time of ESA therapy was similar among patients with native kidney CKD versus kidney recipients, but they achieved a significantly higher hemoglobin (11.04 versus 10.36 g/dL; P < .05). There was no difference between patients administered or not a mammalian target of rapamycin antagonist. None of the patients with native kidney CKD received immunosuppressive therapy, but they were prescribed ACEi more often than kidney recipients. The higher degree of anemia in kidney allograft recipient is the most probably attributed to the use of immunosuppressive drugs, despite their better kidney function and comparable iron status. This study suggested that higher doses of ESA should be employed to anemia in kidney transplant recipients.
Collapse
Affiliation(s)
- J Malyszko
- Department of Nephrology and Transplantology, Medical University, Bialystok, Poland.
| | | | | |
Collapse
|
21
|
Borowiec M, Fendler W, Dusatkova P, Antosik K, Pruhova S, Cinek O, Mysliwiec M, Jarosz-Chobot P, Malecki MT, Mlynarski W. HbA1c-based diabetes diagnosis among patients with glucokinase mutation (GCK-MODY) is affected by a genetic variant of glucose-6-phosphatase (G6PC2). Diabet Med 2012; 29:1465-9. [PMID: 22486180 DOI: 10.1111/j.1464-5491.2012.03671.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIMS Genetic variation at the rs560887 locus of the glucose-6-phosphatase, catalytic 2 gene (G6PC2) is known to affect regulation of fasting glycaemia. We determined the rs560887 genotype of patients with monogenic diabetes and glucokinase gene mutations (GCK-MODY) and correlated the genotypes with HbA(1c) levels. METHODS Patients from families with GCK-MODY were recruited from two large cohorts from Poland (n = 128) and the Czech Republic (n = 154). Genotypes at the rs560887 polymorphic site in G6PC2 were examined using real-time quantitative polymerase chain reaction. The effect of rs560887 genotype on age at diagnosis of GCK-MODY and initial HbA(1c) levels were evaluated separately within both cohorts. Following that, a meta-analysis of rs560887 genotype-HbA(1c) associations of both Polish and Czech cohorts was performed to confirm homogeneity of findings and validate cohort-specific results. RESULTS GG homozygosity at rs560887 was associated with marginally elevated HbA(1c) levels (P = 0.07 in both cohorts). The effects observed in both groups were very homogeneous (Q = 0.18; P = 0.68). Meta-analysis showed that GG homozygosity at rs560887 was associated with mean HbA(1c) levels higher by 2.4 mmol/mol (0.24%), 95% CI 0.5-4.4 mmol/mol (0.05-0.44%) than in individuals with other genotypes. Additionally, meta-analysis of both cohorts showed that GG homozygous individuals had higher odds of reaching the 48 mmol/mol (6.5%) diagnostic threshold of diabetes; (odds ratio 1.90; 95% CI 1.07-3.36; P = 0.03). No such effects were observed for age at diagnosis of diabetes. CONCLUSIONS Variation at the rs560887 locus of G6PC2 is associated with worse glycated haemoglobin levels in individuals with GCK mutations; GG homozygotes are more likely to meet diagnostic criteria for diabetes based on HbA(1c) level.
Collapse
Affiliation(s)
- M Borowiec
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, Poland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Fendler W, Borowiec M, Baranowska-Jazwiecka A, Szadkowska A, Skala-Zamorowska E, Deja G, Jarosz-Chobot P, Techmanska I, Bautembach-Minkowska J, Mysliwiec M, Zmyslowska A, Pietrzak I, Malecki MT, Mlynarski W. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. Diabetologia 2012; 55:2631-2635. [PMID: 22782286 PMCID: PMC3433657 DOI: 10.1007/s00125-012-2621-2] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2012] [Accepted: 05/24/2012] [Indexed: 11/24/2022]
Abstract
AIMS/HYPOTHESIS The aim of this study was to study dynamic changes in the prevalence of different types of diabetes in paediatric populations in Poland, with a specific focus on monogenic diabetes (MD). METHODS Using epidemiologic data (PolPeDiab Collaboration) and nationwide genetic test results (TEAM Programme), we compared the prevalence of type 1, type 2 and cystic fibrosis-related diabetes (CFRD) and MD. Genetically confirmed MD included MODY, neonatal diabetes and Wolfram and Alström syndromes. The study covered all children aged 0-18 years treated for diabetes between 2005 and 2011 in three regions, inhabited by 23.7% (1,989,988) of Polish children, with a low prevalence of childhood obesity (<5%). RESULTS The prevalence of type 1 diabetes showed a continuous increase, from 96 to 138/100,000 children. The prevalence of type 2 diabetes and CFRD also increased, from 0.3 to 1.01/100,000 children and from 0.1 to 0.95/100,000 children, respectively. The prevalence of MD was stable at between 4.2 and 4.6/100,000 children, accounting for 3.1-4.2% of children with diabetes, with glucokinase (GCK)-MODY being the most frequent type, amounting to 83% of patients with MD. The percentage of positive test results decreased with the number of referrals, suggesting that children with the highest probability of MD were referred initially, followed by those with a less clear-cut phenotype. The prevalence of neonatal diabetes equalled 1 in 300,000 children. CONCLUSIONS/INTERPRETATION The prevalence of MD in a paediatric population with a low prevalence of obesity remains stable and is nearly fivefold higher than that of type 2 diabetes and CFRD, justifying a need for increased access to genetic diagnostic procedures in diabetic children.
Collapse
Affiliation(s)
- W Fendler
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland
| | - M Borowiec
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland
| | - A Baranowska-Jazwiecka
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland
| | - A Szadkowska
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland
| | - E Skala-Zamorowska
- Department of Paediatrics, Endocrinology and Diabetes, Silesian Medical University of Katowice, Katowice, Poland
| | - G Deja
- Department of Paediatrics, Endocrinology and Diabetes, Silesian Medical University of Katowice, Katowice, Poland
| | - P Jarosz-Chobot
- Department of Paediatrics, Endocrinology and Diabetes, Silesian Medical University of Katowice, Katowice, Poland
| | - I Techmanska
- Department of Paediatrics, Oncology, Haematology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - J Bautembach-Minkowska
- Department of Paediatrics, Oncology, Haematology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - M Mysliwiec
- Department of Paediatrics, Oncology, Haematology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - A Zmyslowska
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland
| | - I Pietrzak
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland
| | - M T Malecki
- Department of Metabolic Diseases, Collegium Medicum Jagiellonian University of Cracow, Cracow, Poland
| | - W Mlynarski
- Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Lodz, 36/50 Sporna Str., 91-738, Lodz, Poland.
| |
Collapse
|
23
|
Shin SJ, Rhee MY, Lim C, Lavoz C, Rodrigues-Di;ez R, Rayego-Mateos S, Benito-Martin A, Rodrigues-Diez R, Alique M, Ortiz A, Mezzano S, Ruiz-Ortega M, Axelsson J, Axelsson J, Rippe A, Sverrisson K, Rippe B, Calo L, Dal Maso L, Pagnin E, Caielli P, Calo L, Pagnin E, Dal Maso L, Caielli P, Spanos G, Spanos G, Kalaitzidis R, Karasavvidou D, Pappas K, Balafa O, Siamopoulos K, Fang TC, Lee TJF, Spanos G, Spanos G, Kalaitzidis R, Pappas E, Ermeidi E, Tatsioni A, Siamopoulos K, Blazquez-Medela A, Garcia-Sanchez O, Quiros Y, Lopez-Hernandez FJ, Lopez-Novoa JM, Martinez-Salgado C, Wu HY, Peng YS, Hung KY, Tsai TJ, Tu YK, Chien KL, Larsen T, Mose FH, Hansen AB, Pedersen EB, Quiroz Y, Rivero M, Yaguas K, Rodriguez-Iturbe B, Xydakis D, Sfakianaki M, Petra C, Maragaki E, Antonaki E, Krasoudaki E, Kostakis K, Stylianou K, Papadogiannakis A, Sagliker Y, Paylar N, Heidland A, Keck A, Erek R, Kolasin P, S Ozkaynak P, Sagliker HS, Gokcay I, Ritz E, Koleganova N, Gross-Weissmann ML, Piecha G, Reinecke N, Marquez Cunha T, M . S. Higa E, Pfeferman Heilberg I, Neder JA, Nishiura JL, Silva Almeida W, Schor N, Tapia E, Sanchez-Lozada LG, Cristobal M, Soto V, Garci;a-Arroyo F, Monroy-Sanchez F, Madero M, Johnson R, Kim SM, Yang SH, Kim YS, Karanovic S, Fistrek M, Kos J, Pecin I, Premuzic V, Abramovic M, Matijevic V, Cvoriscec D, Cvitkovic A, Knezevic M, Bitunjac M, Laganovic M, Jelakovic B, Liu F, Wu M, Fu P, Klok Matthesen S, Klok Matthesen S, Larsen T, Guldager Lauridsen T, Vase H, Gjorup Holland P, Nykjaer KM, Nielsen S, Bjerregaard Pedersen E, Blazquez-Medela A, Lopez-Hernandez FJ, Garcia-Sanchez O, Quiros Y, Montero MJ, Lopez-Novoa JM, Martinez-Salgado C, Vink E, Willemien V, Michiel V, Wilko S, Evert-Jan V, Blankestijn P, Zerbi S, Pedrini LA, Zbroch E, Zbroch E, Malyszko J, Malyszko J, Koc-Zorawska E, Mysliwiec M, Quelhas-Santos J, Quelhas-Santos J, Serrao P, Soares-Silva I, Tang L, Sampaio-Maia B, Desir G, Pestana M, Elsurer R, Demir T, Celik G, Yavas M, Yavas O, Murphy M, Jacquillet G, Unwin RJ, Chichger H, Shirley DG, Caraba A, Andreea M, Corina S, Ioan R, Nowicki M, Bobik M, Pawelec A, Lacisz J, Zapala A, Bryc K, Esposito C, Scaramuzzi ML, Manini A, Torreggiani M, Beneventi F, Spinillo A, Grosjean F, Fasoli G, Dal Canton A, Christos C, Christos C, Bernhard M.W. S, Martin N, Jan K, Claus M, Leyla R, Jan B, Ulrich K, Hermann H, Menne J, Pavicevic M, Pavicevic M, Markovic S, Igrutinovic Z. Hypertension. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Fusaro M, Fusaro M, Noale M, Tripepi G, D'angelo A, Miozzo D, Gallieni M, Study Group PV, Tsamelesvili M, Dimitriadis C, Papagianni A, Raidis C, Efstratiadis G, Memmos D, Mutluay R, Konca Degertekin C, Derici U, Deger SM, Akkiyal F, Gultekin S, Gonen S, Tacoy G, Arinsoy T, Sindel S, Sanchez-Perales C, Vazquez E, Merino E, Perez Del Barrio P, Borrego FJ, Borrego MJ, Liebana A, Krzanowski M, Janda K, Dumnicka P, Krasniak A, Sulowicz W, Kim YO, Yoon SA, Yun YS, Song HC, Kim BS, Cheong MA, Pasch A, Farese S, Floege J, Jahnen-Dechent W, Ohtake T, Ohtake T, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Ishioka K, Oka M, Maesato K, Moriya H, Hidaka S, Kobayashi S, Guedes A, Malho Guedes A, Pinho A, Fragoso A, Cruz A, Mendes P, Morgado E, Bexiga I, Silva AP, Neves P, Oyake N, Suzuki K, Itoh S, Yano S, Turkmen K, Kayikcioglu H, Ozbek O, Saglam M, Toker A, Tonbul HZ, Gelev S, Trajceska L, Srbinovska E, Pavleska S, Amitov V, Selim G, Dzekova P, Sikole A, Bouarich H, Lopez S, Alvarez C, Arribas I, DE Sequera P, Rodriguez D, Fusaro M, Fusaro M, Noale M, Tripepi G, D'angelo A, Miozzo D, Gallieni M, Study Group PV, Tanaka S, Kanemitsu T, Sugahara M, Kobayashi M, Uchida L, Ishimoto Y, Kotera N, Tanimoto S, Tanabe K, Hara K, Sugimoto T, Mise N, Goldstein B, Turakhia M, Arce C, Winkelmayer W, Zayed BED, Said K, Nishimura M, Nishimura M, Okamoto Y, Tokoro T, Nishida M, Hashimoto T, Iwamoto N, Takahashi H, Ono T, Nishimura M, Okamoto Y, Tokoro T, Sato N, Nishida M, Hashimoto T, Iwamoto N, Takahashi H, Ono T, Guedes A, Malho Guedes A, Cruz A, Morgado E, Pinho A, Fragoso A, Mendes P, Bexiga I, Silva AP, Neves P, Raimann J, Usvyat LA, Sands J, Levin NW, Kotanko P, Iwasaki M, Joki N, Tanaka Y, Ikeda N, Hayashi T, Kubo S, Imamura TA, Takahashi Y, Hirahata K, Imamura Y, Hase H, Claes K, Meijers B, Bammens B, Kuypers D, Naesens M, Vanrenterghem Y, Evenepoel P, Boscutti G, Calabresi L, Bosco M, Simonelli S, Boer E, Vitali C, Martone M, Mattei PL, Franceschini G, Baligh E, Zayed BED, Said K, El-Shafey E, Ezaat A, Zawada A, Rogacev K, Hummel B, Grun O, Friedrich A, Rotter B, Winter P, Geisel J, Fliser D, Heine GH, Makino JI, Makino KS, Ito T, Genovesi S, Santoro A, Fabbrini P, Rossi E, Pogliani D, Stella A, Bonforte G, Remuzzi G, Bertoli S, Pozzi C, Gallieni M, Pasquali S, Cagnoli L, Conte F, Santoro A, Buzadzic I, Tosic J, Dimkovic N, Djuric Z, Popovic J, Pejin Grubisa I, Barjaktarevic N, DI Napoli A, DI Lallo D, Salvatori MF, Franco F, Chicca S, Guasticchi G, Onofriescu M, Hogas S, Luminita V, Mugurel A, Gabriel V, Laura F, Irina M, Adrian C, Bosch E, Baamonde E, Culebras C, Perez G, El Hayek B, Ramirez JI, Ramirez A, Garcia C, Lago M, Toledo A, Checa MD, Taira T, Hirano T, Nohtomi K, Hyodo T, Chiba T, Saito A, Kim YK, Song HC, Choi EJ, Yang CW, Kim YS, Lim PS, Ming Ying W, Ya-Chung J, Zaripova I, Kayukov I, Essaian A, Nimgirova A, Young H, Dungey M, Watson EL, Baines R, Burton JO, Smith AC, Joki N, Iwasaki M, Tanaka Y, Kubo S, Hayashi T, Ikeda N, Yamazaki K, Hase H, Bossola M, Colacicco L, Scribano D, Vulpio C, Tazza L, Okada T, Okada N, Michibata I, Yura T, Montero N, Soler M, Pascual M, Barrios C, Marquez E, Rodriguez E, Orfila MA, Cao H, Arcos E, Comas J, Pascual J, Ferrario M, Garzotto F, Sironi T, Monacizzo S, Basso F, Garzotto F, Cruz DN, Moissl U, Tetta C, Signorini MG, Cerutti S, Ronco C, Mostovaya I, Grooteman M, Van den Dorpel M, Penne L, Van der Weerd N, Mazairac A, Den Hoedt C, Levesque R, Nube M, Ter Wee P, Bots M, Blankestijn P, Liu J, MA KL, Zhang X, Liu BC, Vladu ID, Mustafa R, Cana-Ruiu D, Vaduva C, Grauntanu C, Mota E, Singh R, Abbasian N, Stover C, Brunskill N, Burton J, Abbasian N, Herbert K, Bevington A, Brunskill N, Burton J, Wu M, Tang RN, Gao M, Liu H, Chen L, LV LL, Liu BC, Nikodimopoulou M, Liakos S, Kapoulas S, Karvounis C, Fedak D, Kuzniewski M, Paulina D, Kusnierz-Cabala B, Kapusta M, Solnica B, Sulowicz W, Junque A, Vicent ES, Moreno L, Fulquet M, Duarte V, Saurina A, Pou M, Macias J, Lavado M, Ramirez de Arellano M, Ryuzaki M, Nakamoto H, Kinoshita S, Kobayashi E, Takimoto C, Shishido T, Enia G, Torino C, Tripepi R, Panuccio V, Postorino M, Clementi A, Garozzo M, Bonanno G, Boito R, Natale G, Cicchetti T, Chippari A, Logozzo D, Alati G, Cassani S, Sellaro A, Zoccali C, Quiroga B, Verde E, Abad S, Vega A, Goicoechea M, Reque J, Lopez-Gomez JM, Luno J, Cabre Menendez C, Moles V, Vives JP, Villa D, Vinas J, Compte T, Arruche M, Diaz C, Soler J, Aguilera J, Martinez Vea A, De Mauri A, David P, Conte MM, Chiarinotti D, Ruva CE, De Leo M, Bargnoux AS, Morena M, Jaussent I, Chalabi L, Bories P, Dion JJ, Henri P, Delage M, Dupuy AM, Badiou S, Canaud B, Cristol JP, Fabbrini P, Sironi E, Pieruzzi F, Galbiati E, Vigano MR, Stella A, Genovesi S, Anpalakhan S, Anpalakhan S, Rocha S, Chitalia N, Sharma R, Kaski JC, Chambers J, Goldsmith D, Banerjee D, Cernaro V, Lacquaniti A, Lupica R, Lucisano S, Fazio MR, Donato V, Buemi M, Segalen I, Segalen I, Vinsonneau U, Tanquerel T, Quiniou G, Le Meur Y, Seibert E, Girndt M, Zohles K, Ulrich C, Kluttig A, Nuding S, Swenne C, Kors J, Werdan K, Fiedler R, Van der Weerd NC, Grooteman MP, Bots M, Van den Dorpel MA, Den Hoedt C, Nube MJ, Wetzels J, Swinkels DW, Blankestijn P, Ter Wee PM, Khandekar A, Khandge J, Lee JE, Moon SJ, Choi KH, Lee HY, Kim BS, Morena M, Tuaillon E, Jaussent I, Rodriguez A, Chenine L, Vendrell JP, Cristol JP, Canaud B, Sue YM, Tang CH, Chen YC, Sanchez-Perales C, Vazquez E, Segura P, Garcia Cortes MJ, Gil JM, Biechy MM, Liebana A, Poulikakos D, Shah A, Persson M, Banerjee D, Dattolo P, Amidone M, Amidone M, Michelassi S, Moriconi L, Betti G, Conti P, Rosati A, Mannarino A, Panichi V, Pizzarelli F, Klejna K, Naumnik B, Koc-Zorawska E, Mysliwiec M, Dimitrie S, Simona H, Mihaela O, Mugurel A, Gabriela O, Radu S, Octavian P, Adrian C, Akdam H, Akar H, Yenicerioglu Y, Kucuk O, Kurt Omurlu I, Goldsmith D, Thambiah S, Roplekar R, Manghat P, Manghat P, Fogelman I, Fraser W, Hampson G, Likaj E, Likaj E, Caco G, Seferi S, Rroji M, Barbullushi M, Thereska N, Onofriescu M, Hogas S, Luminita V, Mugurel A, Serban A, Carmen V, Cristian S, Silvia L, Covic A. Cardiovascular complications in CKD 5D. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Adamczak M, Wiecek A, Nowak L, Grzegorzewska AE, Niepolski L, Pajzderski D, Mohamed WAAA, Mohamed WAAA, Khamis Zaki FM, Bekhit WHM, Sherif IS, Lin CC, Chen HY, Chiu YL, Hsu SP, Pai MF, Yang JY, Peng YS, Tsai TJ, Wu KD, Shojai S, Udayaraj U, Shojai P, Zwiech R, Bruzda-Zwiech A, Musial K, Zwolinska D, Grzegorzewska AE, Piotr M. W, Mostowska A, Jagodzinski PP, Ortalda V, Tomei P, Yabarek T, Tobaldini O, Gangemi C, Messa MG, Lupo A, Ebah L, Nikam M, Summers A, Dawidowska I, Jayanti A, Wiig H, Brenchley P, Mitra S, Mikami S, Hamano T, Iba O, Toki M, Mikami H, Takamitsu Y, Fujii M, Dzekova-Vidimliski P, Sikole A, Gelev S, Selim G, Trajceska L, Fujimoto S, Inagaki H, Fukudome K, Ebihara F, Yokota N, Sato Y, Akiba T, Otsubo S, Nitta K, Rydzewska-Rosolowska A, Gozdzikiewicz J, Borawski J, Hryszko T, Koc-Zorawska E, Mysliwiec M, Arias M, Arias M, Banon-Maneus E, Sole A, Hierro-Garcia N, Rovira J, Ramirez-Bajo MJ, Quintana LF, Diekmann F, Moya-Rull D, Maduell F, Campistol JM, Erkmen Uyar M, Toprak SK, Saglam H, Tutal E, Bay M, Ilhan O, Sezer S, Malyszko J, Malyszko J, Kozminski P, Koc-Zorawska E, Zbroch E, Mysliwiec M. Pathophysiology CKD 5D. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs246] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Fliser D, Shilo V, Covic A, Besarab A, Provenzano R, Duliege AM, Chen M, Tong S, Francisco C, Gao HY, Polu K, De Francisco AL, Macdougall I, Macdougall I, Schiller B, Locatelli F, Wiecek A, Francisco C, Tang H, Tong S, Chen M, Duliege AM, Polu K, Mayo M, Covic A, Macdougall I, Macdougall I, Casadevall N, Stead R, Taal M, Faller B, Karras A, Chen M, Tong S, Duliege AM, Rowell R, Polu K, Eckardt KU, Locatelli F, Dusilova Sulkova S, Arnaud S, Bruno P, Arnaud G, Dorina V, Eric A, Gerard M, Cases A, Portoles JM, Calls J, Martinez Castelao A, Sanchez-Guisande D, Segarra A, Tsubakihara Y, Tsubakihara Y, Saito A, Saito A, Saito A, Tsubakihara Y, Martinez-Castelao A, Martinez-Castelao A, Cases A, Fort J, Bonal J, Fulladosa X, Galceran JM, Torregrosa V, Coll E, Minutolo R, Cozzolino M, DI Iorio B, Polito P, Santoro D, Manenti F, Nappi F, Feriozzi S, Conte G, De Nicola L, Mikhail A, Provenzano R, Schiller B, Besarab A, Francisco C, Gao HY, Daley R, Tong S, Mayo M, Yang A, Polu K, Macdougall I, Wiecek A, Schiller B, Canaud B, Locatelli F, Yang A, Chen M, Polu K, Francisco C, Gao HY, Tong S, Duliege AM, Provenzano R, Locatelli F, Locatelli F, Provenzano R, Besarab A, Rath T, Yang A, Mayo M, Francisco C, Macdougall I, Bartnicki P, Baj Z, Majewska E, Rysz J, Fievet P, Assem M, Brazier F, Xu X, Soltani ON, Demontis R, Barsan L, Stancu S, Stancu S, Stanciu A, Capusa C, Petrescu L, Zugravu A, Mircescu G, Malyszko JM, Levin-Iaina N, Malyszko J, Glowinska I, Koc-Zorawska E, Slotki I, Mysliwiec M, Mircescu G, Mircescu G, Capusa C, Stancu S, Barsan L, Grabowski D, Blaga V, Dumitru D, Pchelin I, Shishkin A, Kus T, Usalan C, Tiryaki O, Chin HJ, Chae DW, Kim S, Bertram H, Keller F, Rumjon A, Wood C, Wilson P, Khakoo S, Chai MO, Macdougall IC, Nuria GF, Maria Asuncion F, Jose Maria MG, Carmen C, Paloma Leticia MM, Francisco Javier L, Moniek DG, De Goeij M, Yvette M, Diana G, Friedo D, Nynke H, Lezaic V, Miljkovic B, Petkovic N, Maric I, Vucicevic K, Simic Ogrizovic S, Djukanovic L, Cases A, Martinez-Castelao A, Fort A, Bonal J, Fulladosa X, Galceran JM, Torregrosa V, Coll E, DI Giulio S, DI Giulio S, Galle J, Kiss I, Herlitz H, Wirnsberger G, Claes K, Suranyi M, Guerin A, Winearls C, Addison J, D'souza M, Froissart M, Garrido P, Garrido P, Teixeira M, Costa E, Rodrigues-Santos P, Parada B, Belo L, Alves R, Teixeira F, Santos-Silva A, Reis F, Winearls C, Winearls C, DI Giulio S, Galle J, Kiss I, Herlitz H, Wirnsberger G, Claes K, Suranyi M, Guerin A, Addison J, D'souza M, Fouqueray B, Floris M, Conti M, Cao R, Pili G, Melis P, Matta V, Murgia E, Atzeni A, Binda V, Angioi A, Peri M, Pani A, Besarab A, Belo D, Diamond S, Martin E, Sun C, Lee T, Saikali K, Franco M, Leong R, Neff T, Yu KHP, Tiranathanagul K, Praditpornsilpa K, Katavetin P, Kanjanabuch T, Avihingsanon Y, Tungsanga K, Eiam-Ong S, Macdougall IC, Casadevall N, Percheson P, Potamianou A, Foucher A, Fife D, Vercammen E. Renal anaemia - CKD 1-5. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Przybylowski P, Malyszko J, Malyszko J, Koc-Zorawska E, Mysliwiec M. 670 Urinary Biomarkers in Heart Allograft Recipients in Relation to Kidney Function. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
28
|
Przybylowski P, Koc-Zorawska E, Malyszko JS, Kozlowska S, Mysliwiec M, Malyszko J. Liver fatty-acid-binding protein in heart and kidney allograft recipients in relation to kidney function. Transplant Proc 2012; 43:3064-7. [PMID: 21996226 DOI: 10.1016/j.transproceed.2011.08.038] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Mammalian intracellular fatty-acid-binding proteins (FABPs), a large multigene family, encode 14-kD proteins that are members of a superfamily of lipid-binding proteins. FABPs are tissue specific. Liver-type FABP (L-FABP) can be filtered through the glomerulus owing to its small molecular size, similar to cystatin C, but it is reabsorbed by proximal tubule epithelial cells like other small proteins. In the human kidney, L-FABP is expressed predominantly in proximal tubules. It had been suggested that the presence of L-FABP in urine reflects hypoxic conditions resulting from decreased peritubular capillary flow, serving as a marker of acute kidney injury. The aim of this study was to assess urinary L-FABP in 111 heart and 76 kidney transplant recipients in relation to kidney function. Complete blood count, urea, fasting glucose, creatinine, and the N-terminal fragment of brain natriuretic protein were studied by standard laboratory methods; L-FABP and cystatin C, by ELISA using commercially available kits. Kidney transplant recipients displayed significantly higher L-FABP than heart recipients. Upon univariate analysis, urinary L-FABP correlated, with serum creatinine, cystatin C and estimated glomerular filtration ratio (eGFR) in kidney allograft recipients. However, in heart transplant recipients it was not related to kidney function, as reflected by creatinine or eGFR; was strongly related to cystatin C (r=0.34; P<.001) and urinary creatinine (r=-0.29; P<.01), and NGAL (r=0.29; P<.01). Upon multiple regression analysis, the best predictor of urinary L-FABP in kidney allograft recipients, was eGFR whereas in heart recipients, no parameter independently predicted L-FABP. Successful heart transplantation is associated with kidney injury as reflected by a reduced eGFR; however, in this population, L-FABP did not serve as a marker of kidney function. In contrast, in kidney allograft recipients, L-FABP may be a potential early marker for impaired kidney function/injury.
Collapse
Affiliation(s)
- P Przybylowski
- Department of Cardiovascular Surgery and Transplantatology, Collegium Medicum, Jagiellonian University, John Paul II Hospital, Krakow, Poland.
| | | | | | | | | | | |
Collapse
|
29
|
Przybylowski P, Malyszko J, Glowinska I, Malyszko J, Kozlowska S, Mysliwiec M. Prevalence of Iron Deficiency in Heart and Kidney Allograft Recipients. Transplant Proc 2011; 43:3885-7. [DOI: 10.1016/j.transproceed.2011.08.083] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2011] [Accepted: 08/31/2011] [Indexed: 11/26/2022]
|
30
|
Przybylowski P, Malyszko J, Kozlowska S, Malyszko J, Koc-Zorawska E, Mysliwiec M. Serum Renalase Depends on Kidney Function But Not on Blood Pressure in Heart Transplant Recipients. Transplant Proc 2011; 43:3888-91. [DOI: 10.1016/j.transproceed.2011.08.075] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2011] [Accepted: 08/29/2011] [Indexed: 11/29/2022]
|
31
|
Malyszko J, Przybylowski P, Malyszko J, Koc-Zorawska E, Mysliwiec M. Tumor necrosis factor-related apoptosis-inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients. Transplant Proc 2011; 43:1877-80. [PMID: 21693293 DOI: 10.1016/j.transproceed.2011.03.035] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Accepted: 03/09/2011] [Indexed: 02/07/2023]
Abstract
BACKGROUND Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) was originally identified as the third member of the TNF superfamily to induce apoptosis. TRAIL is normally expressed in many human tissues including kidney. Circulating soluble TRAIL is a negative marker for inflammation and is inversely associated with the mortality risk in chronic kidney disease patients. One increasingly prevalent complication in heart transplant recipients appears to be chronic kidney disease. MATERIALS AND METHODS The aim of the study was to assess TRAIL concentration in 136 heart transplant recipients and 80 prevalent kidney allograft recipients in relation to kidney function. Complete blood count, urea, serum lipids, fasting glucose, creatinine, NT-proBNP were studied. Soluble TRAIL, hsCR P, interleukin-6 (IL-6), von willebrand factor (vWF) were assayed using commercially available kits. RESULTS Heart transplant recipients had significantly higher serum creatinine, urea, cholesterol, triglycerides, fasting glucose, white blood cell count, serum TRAIL and lower estimated glomerular filtration rate than the control group. Similar results were obtained for kidney allograft recipients. Serum TRAIL levels fell, together with decline in glomerular filtration rate in heart transplant patients. Serum TRAIL was related to age, kidney function, erythrocyte count, hemoglobin, NT-proBNP, New York Heart Association class, presence of diabetes, high-density lipoprotein (HDL), IL-6, and ejection fraction. Age and HDL turn out to be predictors of TRAIL in heart transplant recipients. In kidney transplant recipients, TRAIL was related, in univariate analysis, to age, NT-proBNP, time after transplantation, kidney function, and vWF. In multiple regression analysis, predictors of TRAIL were vWF and time after transplantation. CONCLUSION TRAIL may represent a surrogate marker of endothelial dysfunction and atherosclerosis as these processes are accelerated in heart and kidney dysfunction.
Collapse
Affiliation(s)
- J Malyszko
- Department of Nephrology and Transplantology, Medical University, Bialystok, Poland.
| | | | | | | | | |
Collapse
|
32
|
Woodburn K, Holmes C, Fong KL, Sloneker S, Strzemienski P, Solon E, Ryckelynck JP, Lang P, Bataille P, Choukroun G, Esnault V, Knebelman B, Laville M, Fellous M, Legrand E, Portoles J, Vega NJ, Fernandez-Fresnedo G, Perez A, Bea S, Camba MJ, Leistikow F, Heidenreich S, Cases A, Portoles J, Calls J, Martinez Castelao A, Sanchez-Guisande D, Espinel E, Carreno A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A, Shestakova M, Heidenreich S, Tsubakihara Y, Bessho M, Suzuki M, Correa-Rotter R, Niihata K, Tomosugi N, Uehata T, Shoji T, Sonoda M, Kawabata H, Sakaguchi Y, Suzuki A, Okada N, Tsubakihara Y, Kuragano T, Shimonaka Y, Kida A, Kitamura R, Furuta M, Yahiro M, Otaki Y, Nisihara F, Nonoguchi H, Nakanishi T, Mircescu G, Stancu S, Stanciu A, Viasu L, Capusa C, Petrescu L, Zugravu A, Aydin Z, Gursu M, Uzun S, Karadag S, Tatli E, Sumnu A, Doventas Y, Koldas M, Ozturk S, Kazancioglu R, Malyszko Y, Levin-Iaina N, Malyszko J, Kozminski P, Koc-Zorawska E, Mysliwiec M, Hara M, Ando M, Tsuchiya K, Nitta K, Mirescu G, Deray G, Garneata L, Goldsmith D, Gorriz Teruel JL, Martin PY, Mitchell D, Mori C, Schafer R, Guerin A, Addison J, Bridges I, Di Giulio S, Farouk M, Winearls C, Kiss I, Claes K, Galle J, Costa E, Rocha-Pereira P, Sameiro-Faria M, Miranda V, Afonso C, Belo L, Marinho C, Bicho M, Santos-Silva A, Kim HW, Jang EH, Mercadal L, Metzger M, Casadevall N, Haymann JP, Boffa JJ, Flamant M, Vrtovsnik F, Stengel B, Froissart M, Ode M, Roth K, Locatelli F, Horl WH. Anaemia in CKD 1-5. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Kuo KL, Hung SC, Tarng DC, Selim G, Stojceva-Taneva O, Tozija L, Gelev S, Stojcev N, Dzekova P, Trajcevska L, Severova G, Pavleska S, Sikole A, Combe C, Thumma J, Gillespie B, De Sequera P, Yamamoto H, Robinson B, Matsushita Y, Tasaki H, Tohara Y, Yamauchi E, Matsuoka K, Arizono K, Bellasi A, Ferramosca E, Ratti C, Block G, Raggi P, Drozdz M, Krasniak A, Chmiel G, Podolec P, Pasowicz M, Tracz W, Kowalczyk-Michalek M, Sulowicz W, Kalantzi K, Korantzopoulos P, Bechlioulis A, Vlachopanou A, Foulidis V, Pagiati E, Nikolopoulos P, Gouva C, Arroyave I, Rodelo J, Cardona M, Garcia A, Henao J, Mejia G, Rico J, Arbelaez M, Fujimori A, Okada S, Yamamoto K, Okamoto S, Kamiura N, Sakai M, Tanikake M, Kutlay S, Sengul S, Keven K, Nergizoglu G, Erturk S, Ates K, Duman N, Karatan O, Erbay B, Sameiro-Faria M, Costa E, Rocha-Pereira P, Borges A, Nascimento H, Mendonca D, Amado L, Reis F, Miranda V, Quintanilha A, Belo L, Santos-Silva A, Oh JS, Kim SM, Sin YH, Kim JK, Ishihara M, Otsubo S, Kimata N, Akiba T, Nitta K, Kim KM, Baek CH, Kim SB, Testa A, Sanguedolce MC, Spoto B, Mallamaci F, Malatino L, Tripepi G, Zoccali C, Lee JE, Moon SJ, Kim JK, An HR, Ha SK, Pakr HC, Bahlmann FH, Becker E, Sperber V, Triem S, Noll C, Zewinger S, Fliser D, Laufs U, Thijssen S, Usvyat LA, Raimann JG, Balter P, Kotanko P, Levin NW, Hornum M, Bay JT, Clausen P, Melchior Hansen J, Mathiesen ER, Feldt-Rasmussen B, Garred P, Sural S, Panja CS, Bhattacharya SK, Cernaro V, Lacquaniti A, Lorenzano G, Romeo A, Donato V, Buemi M, Raimann JG, Usvyat L, Thijssen S, Rogus J, Lacson E, Kotanko P, Levin NW, Robinson BM, Karaboyas A, Sen A, Hecking M, Mendelssohn D, Jadoul M, Kawanishi H, Saran R, Kolarz M, Undas A, Wyroslak J, Malyszko J, Klejna K, Naumnik B, Koc-Zurawska E, Mysliwiec M, Piecha G, Kuczera P, Adamczak M, Fedorova OV, Bagrov AY, Wiecek A, Gungor O, Kircelli F, Asci G, Carrero JJ, Tatar E, Demirci M, Toz H, Ozkahya M, Ok E, Bansal V, Shareain K, Hoppensteadt D, Litinas E, Fareed J, Kim MJ, Lee SW, Song JH, Kweon J, Kim WH, Sasaki K, Yasuda K, Hatanaka M, Hayashi T, Katsipi I, Tatsiopoulos A, Papanikolaou P, Doulgerakis C, Kollia K, Kardouli E, Asmanis E, Gennadiou M, Kyriazis J, Panizo S, Barrio-Vazquez S, Carrillo-Lopez N, Fernandez-Vazquez A, Braga S, Rodriguez-Rebollar A, Naves-Diaz M, Cannata-Andia JB, Nikodimopoulou M, Liakos S, Kapoulas S. Cardiovascular complications in CKD 5D (1). Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Pawlak D, Mysliwiec M, Pawlak K. 343 3-HYDROXYKYNURENINE – A NEW FACTOR ASSOCIATED WITH CAROTID ATHEROSCLEROSIS, OXIDATIVE STRESS AND INFLAMMATION IN URAEMIA. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70344-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Malyszko J, Koc-Zorawska E, Malyszko JS, Mysliwiec M. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients. Transplant Proc 2011; 42:3957-9. [PMID: 21168598 DOI: 10.1016/j.transproceed.2010.10.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2010] [Revised: 09/22/2010] [Accepted: 10/06/2010] [Indexed: 12/13/2022]
Abstract
INTRODUCTION KIM-1 (kidney injury molecule-1) is responsible for the clearance of debris from damaged renal tubules. KIM-1 can be expressed and excreted in urine within 12 hours after the initial ischemic insult and before regeneration of the epithelium, persisting over time thereafter. Urinary KIM-1 has been reported to be a noninvasive, rapid, sensitive, and reproducible biomarker of experimental nephrotoxic and ischemic acute kidney injury. Renal KIM-1 expression is significantly increased in human kidney tissue among patients with a wide range of kidney diseases, including various types of glomerulonephritis, chronic allograft nephropathy, acute rejection, hypertension, and Wegener's granulomatosis. Both renal and urinary KIM-1 correlate with kidney damage and negatively with renal function, but not with proteinuria. The aim of this study was to assess whether urinary KIM-1 correlated with kidney function in kidney allograft recipients. METHODS Serum NGAL, creatinine and estimated glomerular filtration rate (eGFR) were evaluated in 170 kidney allograft recipients on therapy with a calcineurin inhibitor plus mycophenolate mofetil or azathioprine and prednisone as well as in healthy volunteers. KIM-1 was estimated in urine using a commercially available kit. RESULTS Kidney transplant recipients showed significantly higher KIM-1 values than the control group. Normotensive kidney allograft recipients displayed significantly lower NGAL results than hypertensive subjects. Urinary KIM-1 was significantly higher among diabetic than nondiabetic subjects, whereas creatinine did not differ significantly between them. Upon univariate analysis urinary KIM-1 strongly correlated with serum creatinine (r = .64) and eGFR (r = -.71), and only weakly with other parameters. Upon multiple regression analysis, the best predictor of urinary KIM-1 was eGFR (beta -0.61), which explained 61% of KIM-1 concentrations. CONCLUSION Even a successful kidney transplantation is associated with kidney injury as reflected by elevated urinary KIM-1 and lower eGFR. Therefore, KIM-1 needs to be investigated as a potential early marker for impaired renal function/kidney injury, especially in patients with other risk factors for damage such as hypertension or diabetes.
Collapse
Affiliation(s)
- J Malyszko
- Department of Nephrology and Transplantology, Medical University, Bialystok, Poland.
| | | | | | | |
Collapse
|
36
|
Malyszko J, Przybylowski P, Koc-Zorawska E, Iaina-Levin N, Sadowski J, Mysliwiec M, Malyszko JS. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients. Transplant Proc 2011; 42:4259-62. [PMID: 21168678 DOI: 10.1016/j.transproceed.2010.09.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2010] [Accepted: 09/03/2010] [Indexed: 11/29/2022]
Abstract
Copeptin is cosynthesized with vasopressin, also known as antidiuretic hormone. It is more stable than vasopressin. Recently copeptin has been studied as a diagnostic and prognostic marker for various diseases. Among patients with destabilized heart failure, copeptin was an accurate prognostic marker for mortality. Chronic heart failure is present in more than one-third of incident dialysis patients as well as in kidney allograft recipients. The aim of this study was to assess copeptin in orthotopic heart and kidney allograft recipients in relation to New York Heart Association (NYHA) class and kidney function. The studies were performed on 134 prevalent patients including 103 males and 31 females after orthotopic heart (OHT) and 80 prevalent kidney allograft recipients including 51 males and 29 females. Glomerular filtration rate (GFR) was estimated using the simplified MDRD and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae. We measured complete blood count, urea, serum lipids, fasting glucose, creatinine, NT-proBNP using standard methods in the central laboratory of the hospital. Plasma copeptin, estimated using a commercially available kit, was correlated with kidney function parameters of creatinine, estimated GFR by MDRD and CKD-EPI, NT-proBNP and ejection fraction. Copeptin was significantly lower among kidney allograft than orthotopic heart recipients: 0.71 ± 0.13 ng/mL versus 0.99 ± 0.36 ng/mL (P < .001). Kidney allograft recipients were significantly younger, with shorter times after transplantation, but similar serum creatinine and estimated GFR values. Kidney allograft recipients displayed lower NYHA classes. Copeptin was higher in chronic kidney disease stage 4 than stage 2; similarly in NYHA class III versus I. However, these correlations did not achieve statistical significance. There was no effect of gender, diabetes, or hypertension on copeptin levels in either group of transplanted patients. Among the heart transplant population copeptin is independently associated with kidney and heart function, but not in kidney allograft recipients. It may also predict outcomes of orthotopic heart transplant patients.
Collapse
Affiliation(s)
- J Malyszko
- Department of Nephrology and Transplantology, Medical University, Bialystok, Poland
| | | | | | | | | | | | | |
Collapse
|
37
|
Borowiec M, Antosik K, Fendler W, Deja G, Jarosz-Chobot P, Mysliwiec M, Zmyslowska A, Malecki M, Szadkowska A, Mlynarski W. Novel glucokinase mutations in patients with monogenic diabetes - clinical outline of GCK-MD and potential for founder effect in Slavic population. Clin Genet 2011; 81:278-83. [PMID: 21348868 DOI: 10.1111/j.1399-0004.2011.01656.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Glucokinase (GCK) gene mutations are the causative factor of GCK-MD (monogenic diabetes) characterized by a mild clinical phenotype and potential for insulin withdrawal. This study presents the results of a nationwide genetic screening for GCK-MD performed in Poland. A group of 194 patients with clinical suspicion of GCK-MD and 17 patients with neonatal diabetes were subjected to GCK sequencing. Patients negative for GCK mutations were subjected to multiplex ligation-dependent probe amplification (MLPA) to detect deletions or insertions. A total of 44 GCK heterozygous mutations were found in 68 probands (35%). Among those, 20 mutations were novel ones: A282fs, D198V, E158X, G246V, G249R, I348N, L165V, L315Q, M115I, N254S, P284fs, Q338P, R377L, R43C, R46S, S212fs, S212P, T255N, V406A and Y214D. No abnormalities were detected in MLPA analysis. Homozygous D278E mutation was found in one patient with neonatal diabetes. The most frequently observed combinations of symptoms typical for GCK-MD were mild diabetes and/or fasting hyperglycaemia (98.3%), positive C-peptide at diagnosis (76%) and dominant mode of inheritance (59%). This study outlines numerous novel mutations of the GCK gene present in white Caucasians of Slavic origin. Thorough clinical assessment of known factors associated with GCK-MD may facilitate patient selection.
Collapse
Affiliation(s)
- M Borowiec
- Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Jarosz-Chobot P, Polanska J, Szadkowska A, Kretowski A, Bandurska-Stankiewicz E, Ciechanowska M, Deja G, Mysliwiec M, Peczynska J, Rutkowska J, Sobel-Maruniak A, Fichna P, Chobot A, Rewers M. Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia 2011; 54:508-15. [PMID: 21165594 PMCID: PMC3034048 DOI: 10.1007/s00125-010-1993-4] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2010] [Accepted: 09/23/2010] [Indexed: 01/08/2023]
Abstract
AIMS/HYPOTHESIS We analysed the temporal changes in the incidence of childhood type 1 diabetes and its demographic determinants in Poland from 1989 to 2004, validating the model with data from 1970 to 1989. We also estimated a predictive model of the trends in childhood diabetes incidence for the near future. METHODS Children under 15 years with newly diagnosed type 1 diabetes mellitus and drawn from seven regional registries in Poland were ascertained prospectively using the Epidemiology and Prevention of Diabetes study (EURODIAB) criteria. The type 1 diabetes incidence rates (IRs) were analysed in dependency of age, sex, seasonality, geographical region and population density. Time trends in IR were modelled using several approaches. RESULTS The average incidence, standardised by age and sex, for 1989 to 2004 was 10.2 per 100,000 persons per year and increased from 5.4 to 17.7. No difference was found between boys and girls, or between urban and rural regions. In children above 4 years, IR was significantly higher in the population of northern Poland than in that of the country's southern part, as well as in the autumn-winter season, this finding being independent of child sex. Based on the trend model obtained, almost 1,600 Polish children aged 0 to 14 years are expected to develop type 1 diabetes in 2010, rising to more than 4,800 in 2025. The estimates suggest at least a fourfold increase of IR between 2005 and 2025, with the highest dynamics of this increment in younger children. CONCLUSIONS/INTERPRETATION These estimates show that Poland will have to face a twofold higher increase in childhood type 1 diabetes than predicted for the whole European population. The dramatic increase could have real downstream effects on Poland's healthcare system.
Collapse
Affiliation(s)
- P Jarosz-Chobot
- Department of Pediatrics, Endocrinology and Diabetes, Medical University of Silesia, Medykow 16 Str., 40-752, Katowice, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Guldbrand D, Goetzsche O, Eika B, Watanabe N, Taniguchi M, Akagi T, Koide N, Sano S, Orbovic B, Obrenovic-Kircanski B, Ristic S, Soskic LJ, Alhabshan F, Jijeh A, Abo Remsh H, Alkhaldi A, Najm HK, Gasior Z, Skowerski M, Kulach A, Szymanski L, Sosnowski M, Wang M, Siu CW, Lee K, Yue WS, Yan GH, Lee S, Lau CP, Tse HF, O'connor K, Rosca M, Magne J, Romano G, Moonen M, Pierard LA, Lancellotti P, Floria M, De Roy L, Blommaert D, Jamart J, Dormal F, Lacrosse M, Arsenescu Georgescu C, Mizariene V, Bucyte S, Bertasiute A, Pociute E, Zaliaduonyte-Peksiene D, Baronaite-Dudoniene K, Sileikiene R, Vaskelyte J, Jurkevicius R, Dencker M, Thorsson O, Karlsson MK, Linden C, Wollmer P, Andersen LB, Catalano O, Perotti MR, Colombo E, De Giorgi M, Cattaneo M, Cobelli F, Priori SG, Ober C, Iancu Adrian IA, Andreea Parv PA, Cadis Horatiu CH, Ober Mihai OM, Chmielecki M, Fijalkowski M, Galaska R, Dubaniewicz W, Lewicki L, Targonski R, Ciecwierz D, Puchalski W, Koprowski A, Rynkiewicz A, Hristova K, La Gerche A, Katova TZ, Kostova V, Simova Y, Kempny A, Diller GP, Orwat S, Kaleschke G, Kerckhoff G, Schmidt R, Radke RM, Baumgartner H, Smarz K, Zaborska B, Jaxa-Chamiec T, Maciejewski P, Budaj A, Kiotsekoglou A, Govind SC, Gadiyaram V, Moggridge JC, Govindan M, Gopal AS, Ramesh SS, Brodin LA, Saha SK, Ramzy IS, Lindqvist P, Lam YY, Duncan AM, Henein MY, Craciunescu IS, Serban M, Iancu M, Revnic C, Popescu BA, Alexandru D, Rogoz D, Uscatescu V, Ginghina C, Careri G, Di Monaco A, Nerla R, Tarzia P, Lamendola P, Sestito A, Lanza GA, Crea F, Giannini F, Pinamonti B, Santangelo S, Perkan A, Vitrella G, Rakar S, Merlo M, Della Grazia E, Salvi A, Sinagra G, Scislo P, Kochanowski J, Piatkowski R, Roik M, Postula M, Opolski G, Castillo J, Herszkowicz N, Ferreira C, Lonnebakken MT, Staal EM, Nordrehaug JE, Gerdts E, Przewlocka-Kosmala M, Orda A, Karolko B, Bajraktari G, Lindqvist P, Gustafsson U, Holmgren A, Henein MY, Frattini S, Faggiano P, Zilioli V, Locantore E, Longhi S, Bellandi F, Faden G, Triggiani M, Dei Cas L, Seo SM, Jung HO, An SH, Jung SY, Park CS, Jeon HK, Youn HJ, Chung WB, Kim JH, Uhm JS, Mampuya W, Brochu MC, Do DH, Essadiqi B, Farand P, Lepage S, Daly MJ, Monaghan M, Hamilton A, Lockhart C, Kodoth V, Maguire C, Morton A, Manoharan G, Spence MS, Streb W, Mitrega K, Nowak J, Duszanska A, Szulik M, Kalinowski M, Kukulski T, Kalarus Z, Calvo Iglesias FE, Solla-Ruiz I, Villanueva-Benito I, Paredes-Galan E, Bravo-Amaro M, Iniguez-Romo A, Yildirimturk O, Helvacioglu FF, Tayyareci Y, Yurdakul S, Demiroglu IC, Aytekin S, Enache R, Piazza R, Muraru D, Roman-Pognuz A, Popescu BA, Calin A, Leiballi E, Antonini-Canterin F, Ginghina C, Nicolosi GL, Ridard C, Bellouin A, Thebault C, Laurent M, Donal E, Sutandar A, Siswanto BB, Irmalita I, Harimurti G, Saxena A, Ramakrishnan S, Roy A, Krishnan A, Misra P, Bhargava B, Poole-Wilson PA, Loegstrup BB, Andersen HR, Poulsen SH, Klaaborg KE, Egeblad HE, Gu X, Gu XY, He YH, Li ZA, Han JC, Chen J, Mansencal N, Mitry E, Rougier P, Dubourg O, Villarraga H, Adjei-Twum K, Cudjoe TKM, Clavell A, Schears RM, Cabrera Bueno F, Molina Mora MJ, Fernandez Pastor J, Linde Estrella A, Pena Hernandez JL, Isasti Aizpurua G, Carrasco Chinchilla F, Barrera Cordero A, Alzueta Rodriguez FJ, De Teresa Galvan E, Gaetano Contegiacomo GC, Francesco Pollice FP, Paolo Pollice PP, Gu X, Gu XY, He YH, Li ZA, Kontos MC, Shin DH, Yoo SY, Lee CK, Jang JK, Jung SI, Song SI, Seo SI, Cheong SS, Peteiro J, Perez-Perez A, Bouzas-Mosquera A, Pineiro M, Pazos P, Campo R, Castro-Beiras A, Gaibazzi N, Rigo F, Sartorio D, Reverberi C, Sitia S, Tomasoni L, Gianturco L, Ghio L, Stella D, Greco P, De Gennaro Colonna V, Turiel M, Sitia S, Tomasoni L, Cicala S, Magagnin V, Caiani E, Turiel M, Kyrzopoulos S, Tsiapras D, Domproglou G, Avramidou E, Voudris V, Wierzbowska-Drabik K, Lipiec P, Chrzanowski L, Roszczyk N, Kupczynska K, Kasprzak JD, Sachpekidis V, Bhan A, Gianstefani S, Reiken J, Paul M, Pearson P, Harries D, Monaghan MJ, Dale K, Stoylen A, Saha SK, Kodali V, Toole R, Govind SC, Moggridge JC, Kiotsekoglou A, Gopal AS, Raju P, Mcintosh RA, Silberbauer J, Baumann O, Patel NR, Sulke N, Trivedi U, Hyde J, Venn G, Lloyd G, Wejner-Mik P, Lipiec P, Wierzbowska K, Kasprzak JD, Lowenstein JA, Caniggia C, Garcia A, Amor M, Casso N, Lowenstein Haber D, Porley C, Zambrana G, Daru V, Deljanin Ilic M, Ilic S, Kalimanovska Ostric D, Stoickov V, Zdravkovic M, Paraskevaidis I, Ikonomidis I, Parissis J, Papadopoulos C, Stasinos V, Bistola V, Anastasiou-Nana M, Gudin Uriel M, Balaguer Malfagon JR, Perez Bosca JL, Ridocci Soriano F, Martinez Alzamora N, Paya Serrano R, Ciampi Q, Pratali L, Della Porta M, Petruzziello B, Villari B, Picano E, Sicari R, Rosner A, Avenarius D, Malm S, Iqbal A, Baltabaeva A, Sutherland GR, Bijnens B, Myrmel T, Andersen M, Gustafsson F, Secher NH, Brassard P, Jensen AS, Hassager C, Madsen PL, Moller JE, Mampuya W, Brochu MC, Coutu M, Do DH, Essadiqi B, Farand P, Greentree D, Normandin D, Lepage S, Brun H, Dipchand A, Koopman L, Fackoury CT, Truong S, Manlhiot C, Mertens L, Baroni M, Mariani M, Chabane HK, Berti S, Ripoli A, Storti S, Glauber M, Scopelliti PA, Antongiovanni GB, Personeni D, Saino A, Tespili M, Jung P, Mueller M, Jander F, Sohn HY, Rieber J, Schneider P, Klauss V, Agricola E, Slavich M, Stella S, Ancona M, Oppizzi M, Bertoglio L, Melissano G, Margonato A, Chiesa R, Cejudo Diaz Del Campo L, Mesa Rubio D, Ruiz Ortiz M, Delgado Ortega M, Villanueva Fernandez E, Lopez Aguilera J, Toledano Delgado F, Pan Alvarez-Ossorio M, Suarez De Lezo Cruz Conde J, Lafuente M, Butz T, Meissner A, Lang CN, Prull MW, Plehn G, Trappe HJ, Nair SV, Lee L, Mcleod I, Whyte G, Shrimpton J, Hildick Smith D, James PR, Slikkerveer J, Appelman YEA, Veen G, Porter TR, Kamp O, Colonna P, Ten Cate FJ, Bokor D, Daponte A, Cocciolo M, Bona M, Sacchi S, Becher H, Chai SC, Tan PJ, Goh YS, Ong SH, Chow J, Lee LL, Goh PP, Tong KL, Kakihara R, Naruse C, Hironaka H, Tsuzuku T, Ozawa K, Tomaszuk-Kazberuk A, Sobkowicz B, Malyszko J, Malyszko JS, Kalinowski M, Sawicki R, Hirnle T, Dobrzycki S, Mysliwiec M, Musial WJ, Mathias W, Kowatsch I, Saroute ALR, Osorio AFF, Sbano JCN, Ramires JAF, Tsutsui JM, Sakata K, Ito H, Ishii K, Sakuma T, Iwakura K, Yoshino H, Yoshikawa J, Shahgaldi K, Lopez A, Fernstrom B, Sahlen A, Winter R, Kovalova S, Necas J, Amundsen BH, Jasaityte R, Kiss G, Barbosa D, D'hooge J, Torp H, Szmigielski CA, Newton JD, Rajpoot K, Noble JA, Kerber R, Becher H, Koopman LP, Slorach C, Chahal N, Hui W, Sarkola T, Manlhiot C, Bradley TJ, Jaeggi ET, Mccrindle BW, Mertens L, Staron A, Gasior Z, Jasinski M, Wos S, Sengupta P, Wierzbowska-Drabik K, Chrzanowski L, Kasprzak JD, Hayat D, Kloeckner M, Nahum J, Dussault C, Dubois Rande JL, Gueret P, Lim P, King GJ, Brown A, Ho E, Amuntaser I, Bennet K, Mc Elhome N, Murphy RT, Cooper RM, Somauroo JD, Shave RE, Williams KL, Forster J, George C, Bett T, George KP, D'andrea A, Riegler L, Cocchia R, Golia E, Gravino R, Salerno G, Citro R, Caso PIO, Bossone E, Calabro' R, Crispi F, Bijnens B, Figueras F, Bartrons J, Eixarch E, Le Noble F, Ahmed A, Gratacos E, Shang Q, Yip WK, Tam LS, Zhang Q, Lam YY, Li CM, Wang T, Ma CY, Li KM, Yu CM, Dahlslett T, Helland I, Edvardsen T, Skulstad H, Magda LS, Florescu M, Ciobanu A, Dulgheru R, Mincu R, Vinereanu D, Luckie M, Chacko S, Nair S, Mamas M, Khattar RS, El-Omar M, Kuch-Wocial A, Pruszczyk P, Szmigielski CA, Szulc M, Styczynski G, Sinski M, Kaczynska A, Bajraktari G, Vela Z, Haliti E, Hyseni V, Olloni R, Rexhepaj N, Elezi S, Henein MY, Onaindia JJ, Quintana O, Cacicedo A, Velasco S, Alarcon JJ, Morillas M, Rumoroso JR, Zumalde J, Lekuona I, Laraudogoitia Zaldumbide E, Haliti E, Bajraktari G, Poniku A, Ahmeti A, Elezi S, Henein MY, Duncan RF, Mccomb JM, Pemberton J, Lord SW, Leong D, Plummer C, Macgowan G, Grubb N, Leung M, Kenny A, Prinz C, Voigt JU, Zaidi A, Heatley M, Abildstrom SZ, Hvelplund A, Berning J, Saha SK, Toole R, Govind S, Kiotsekoglou A, Brodin L, Gopal A, Castaldi B, Di Salvo G, Santoro G, Gaio G, Palladino MT, Iacono C, Pacileo G, Russo MG, Calabro R, Wang YS, Dong LL, Shu XH, Pan CZ, Zhou DX, Sen T, Tufekcioglu O, Ozdemir M, Tuncez A, Uygur B, Golbasi Z, Kisacik H, Delfino L, De Leo FD, Chiappa LC, Abdel Ghani B, Schiavina R, Salvade P, Morganti A, Bedogni F, Mahia P, Gutierrez L, Pineda V, Garcia B, Otaegui I, Rodriguez JF, Gonzalez MT, Descalzo M, Evangelista A, Garcia-Dorado D, Bruin De- Bon HACM, Van Den Brink RBA, Surie S, Bresser P, Vleugels J, Eckmann HM, Samson DA, Bouma BJ, Dedobbeleer C, Antoine M, Remmelink M, Unger P, Roosens B, Hmila I, Hernot S, Droogmans S, Van Camp G, Lahoutte T, Muyldermans S, Cosyns B, Feltes G, Serra V, Azevedo O, Barbado J, Herrera J, Rivera A, Paniagua J, Valverde V, Torras J, Arriba G, Christodoulides T, Ioannides M, Simamonian K, Yiangou K, Myrianthefs M, Nicolaides E, Dedobbeleer C, Pandolfo M, Unger P, Kleijn SA, Aly MFAA, Terwee CB, Van Rossum AC, Kamp O, Delgado V, Shanks M, Siebelink HM, Sieders A, Lamb H, Ajmone Marsan N, Westenberg J, De Roos A, Schuijf JD, Bax JJ, Anwar AM, Nosir Y, Chamsi-Pasha H, Tschernich HD, Seeburger J, Borger M, Mukherjee C, Mohr FW, Ender J, Obase K, Okura H, Yamada R, Miyamoto Y, Saito K, Imai K, Hayashida A, Watanabe N, Yoshida K. Poster session III * Friday 10 December 2010, 08:30-12:30. European Journal of Echocardiography 2010. [DOI: 10.1093/ejechocard/jeq144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
40
|
Malyszko J, Przybylowski P, Malyszko J, Iaina-Levin N, Sadowski J, Mysliwiec M. Prevalence of Chronic Kidney Disease in Orthotopic Heart Transplant Recipients and Kidney Allograft Recipients Using the New Chronic Kidney Disease Epidemiology Collaboration Formula. Transplant Proc 2010; 42:4251-4. [DOI: 10.1016/j.transproceed.2010.09.033] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2010] [Accepted: 09/03/2010] [Indexed: 10/18/2022]
|
41
|
Przybylowski P, Malyszko J, Malyszko J, Kobus G, Sadowski J, Mysliwiec M. Blood Pressure Control in Orthotopic Heart Transplant and Kidney Allograft Recipients Is Far From Satisfactory. Transplant Proc 2010; 42:4263-6. [DOI: 10.1016/j.transproceed.2010.09.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2010] [Accepted: 09/03/2010] [Indexed: 01/25/2023]
|
42
|
Malyszko J, Przybylowski P, Malyszko JS, Sadowski J, Mysliwiec M. INADEQUATE BLOOD PRESSURE CONTROL IN ORTHOTOPIC HEART TRANSPLANT AND KIDNEY ALLOGRAFT RECIPIENTS: PP.9.381. J Hypertens 2010. [DOI: 10.1097/01.hjh.0000378705.37967.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
43
|
Pawlak K, Tankiewicz J, Mysliwiec M, Pawlak D. MS188 SYSTEMIC LEVELS OF METALLOPROTEINASE-2/ITS INHIBITOR SYSTEM ARE ASSOCIATED WITH QUINOLINIC ACID LEVELS IN PATIENTS WITH CARDIOVASCULAR DISEASE ON PERITONEAL DIALYSIS. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70689-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
44
|
Hryszko T, Brzosko S, Rydzewska-Rosolowska A, Mysliwiec M. Abnormal serum protein electrophoresis in haemodialysis patients. Clin Kidney J 2009. [DOI: 10.1093/ndtplus/sfp182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Malyszko J, Malyszko J, Mysliwiec M. A Possible Role of Hepcidin in the Pathogenesis of Anemia Among Kidney Allograft Recipients. Transplant Proc 2009; 41:3056-9. [DOI: 10.1016/j.transproceed.2009.08.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
46
|
Malyszko J, Malyszko JS, Takada A, Takada Y, Mysliwiec M. Original Article: Cyclosporine a and FK 506 Affect Platelet Functions in Vitro. Platelets 2009; 6:366-70. [DOI: 10.3109/09537109509078473] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
47
|
Pawlak K, Brzosko S, Mysliwiec M, Pawlak D. Abstract: P1230 KYNURENINE, QUINOLINIC ACID – THE NEW FACTORS LINKED TO CAROTID ATHEROSCLEROSIS IN PATIENTS WITH END-STAGE RENAL DISEASE. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71247-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
48
|
Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009; 41:150-3. [PMID: 19249500 DOI: 10.1016/j.transproceed.2008.10.086] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 08/21/2008] [Accepted: 10/15/2008] [Indexed: 02/07/2023]
Abstract
Visfatin, a ubiquitous adipokine, was first described in 2005. It was found to be selectively up-regulated in the adipose tissue and to have insulin-mimetic effects. It has been reported that visfatin is associated with endothelial damage in chronic kidney disease. We investigated plasma visfatin levels (using commercially available kits) in 100 clinically stable kidney allograft recipients. We assessed visfatin markers of coagulation: thrombin-antithrombin complexes, prothrombin fragments 1 + 2; fibrinolysis: tissue plasminogen activator, plasminogen activator inhibitor, plasmin-antiplasmin complexes; endothelial function/injury: von Willebrand factor, thrombomodulin, intracellular adhesion molecule, vascular cell adhesion molecule (VCAM); inflammation: hsCRP and interleukin-6. Visfatin was significantly higher in kidney allograft recipients than in healthy volunteers. Visfatin did not differ significantly between diabetic and nondiabetics, hypertensives and normotensives, patients with and without coronary artery disease, and between male and female subjects. Type of immunosuppressive regimen (mycophenolate mofetil vs azathioprine) did not affect visfatin levels. On univariate analysis, visfatin correlated positively with prothrombin fragments 1 + 2, VCAM, creatinine, high-sensitivity C-reactive protein, and negatively with albumin. In multivariate analysis, only VCAM was associated with visfatin in kidney allograft recipients. Visfatin, which is related to markers of inflammation, may represent a novel link between inflammation and adipocytokines among long-term kidney transplant recipients.
Collapse
Affiliation(s)
- J Malyszko
- Department of Nephrology and Transplantology, Medical University, Bialystok, Poland.
| | | | | |
Collapse
|
49
|
Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 2009; 40:3466-9. [PMID: 19100414 DOI: 10.1016/j.transproceed.2008.06.059] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2007] [Revised: 05/14/2008] [Accepted: 06/18/2008] [Indexed: 10/21/2022]
Abstract
Apelin, a newly discovered adipocytokine produced by white adipose tissue, is also expressed in kidney and heart. It has been reported that apelin is related to echocardiographic features in hemodialyzed patients. Cardiovascular disease is a major contributor to the mortality and morbidity among patients with chronic renal failure as well as kidney allograft recipients. The aim of this study was to assess the association between apelin and coronary artery disease (CAD) among kidney allograft recipients. We investigated plasma apelin levels in 100 clinically stable, kidney allograft recipients with versus without CAD. We also assessed markers of endothelial cell injury-von Villebrand factor (vWF), thrombomodulin, intracellular adhesion molecule (ICAM), and CD146; markers of inflammation-high-sensitivity-reactive protein (hsCRP); other hemostatic parameters-tissue plasminogen activator (tPA) and its inhibitor (PAI-1); as well as other adipocytokines-adiponectin and resistin-using commercially available kits. Markers of endothelial dysfunction and inflammation were significantly elevated among patients with CAD levels, as well as with CAD or diabetes, compared with those without CAD. Apelin was significantly lower among patients with CAD, but higher in diabetic patients. Apelin content was similar in hypertensive versus normotensive kidney allograft recipients. We observed significant correlations between apelin and ICAM, resistin, adiponectin, calcium, phosphate, alanine and aspartate aminotransferase levels, with CAD or diabetes. Upon multiple regression analysis as well as CAD, adiponectin, and ICAM were predictors of apelin. Apelin was significantly reduced in kidney allograft recipients with CAD; its level was predicted by the presence of CAD, endothelial damage, or inflammation. Apelin and other adipocytokines may be associated with inflammation and its clinical consequences.
Collapse
Affiliation(s)
- J Malyszko
- Department of Nephrology, Medical University, Bialystok, Poland.
| | | | | | | | | |
Collapse
|
50
|
Malyszko J, Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M. Neutrophil Gelatinase-Associated Lipocalin Is a New and Sensitive Marker of Kidney Function in Chronic Kidney Disease Patients and Renal Allograft Recipients. Transplant Proc 2009; 41:158-61. [DOI: 10.1016/j.transproceed.2008.10.088] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 09/13/2008] [Accepted: 10/15/2008] [Indexed: 10/21/2022]
|